title: Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
abstract: BACKGROUND
  Dementia with Lewy bodies (DLB) is a common cause of neurodegenerative dementia of old age. Its accurate recognition can be important in clinical management and is essential for the development of disease-modifying treatments. The current clinical diagnostic criteria are limited particularly by relatively poor sensitivity. Dopamine transporter (DAT) imaging using single-photon emission computed tomography (SPECT) is the most highly developed supplementary test for DLB, and is now incorporated as a suggestive feature in the consensus diagnostic criteria. However, there is uncertainty about its accuracy and its place in clinical practice. It is most commonly used in people who are already suspected of having DLB.
  
  
  OBJECTIVE
  We had two objectives in this review: (A) to estimate the accuracy of DAT imaging for the diagnosis of DLB in people with dementia in secondary care (specialist dementia services), and (B) to estimate the accuracy of DAT imaging for the diagnosis of DLB in people with dementia in secondary care who are already suspected of having DLB on the basis of a prior clinical work-up.
  
  
  METHODS
  We searched MEDLINE (1946 to February 2013), Embase (1980 to February 2013), BIOSIS Previews (1926 to February 2013), PsycINFO (1806 to February 2013), CINAHL (1982 to February 2013), LILACS (February 2013) and Web of Science and Conference Proceedings (ISI Web of Science) (1945 to February 2013). Several of these sources contain conference abstracts. We also searched four specialised databases containing diagnostic reviews: Meta-analyses van Diagnostisch Onderzoek (MEDION; February 2013), Database of Abstracts of Reviews of Effects (DARE; February 2013), Health Technology Assessment Database (HTA; February 2013), and Aggressive Research Intelligence Facility (ARIF; February 2013). We checked reference lists of relevant studies and reviews for potential additional studies. Terms for electronic database searching were devised in conjunction with the team at the Cochrane Dementia and Cognitive Improvement Group.
  
  
  METHODS
  
  
  
  METHODS
  We included test accuracy studies with delayed verification, diagnostic case-control studies, and two-gate studies with alternative diagnosis controls.
  
  
  METHODS
  (A) participants with dementia in secondary care, (B) participants in secondary care meeting consensus clinical criteria (other than the DAT imaging criterion) for possible or probable DLB, or both.
  
  
  METHODS
  SPECT or positron emission tomography (PET) imaging of brain dopamine transporters. Reference standard: Neuropathological diagnosis at autopsy.
  
  
  METHODS
  Two review authors independently selected studies for inclusion and extracted data. We extracted results into a 2x2 table, showing the binary test results cross-classified with the binary reference standard. We used this data to calculate sensitivities, specificities, and their 95% confidence intervals. We used the QUADAS-2 tool plus some additional items to assess methodological quality.
  
  
  RESULTS
  We included one study that was applicable to our first objective (A). It reported data on 22 participants who met consensus clinical criteria for DLB or National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimer's disease, or both (a two-gate design with alternative diagnosis controls). The index test was SPECT scanning using the ligand (123)I-FP-CIT. We considered the study to be at high risk of bias in the participant selection and index test domains (QUADAS-2). (123)I-FP-CIT SPECT analysed semiquantitatively had a sensitivity of 1.00 (95% confidence interval (CI) 0.66 to 1.00) and a specificity of 0.92 (95% CI 0.64 to 1.00) for the diagnosis of DLB (n = 22, 1 study). Analysed visually, the sensitivity was 0.86 (95% CI 0.42 to 1.00) and the specificity was 0.83 (95% CI 0.52 to 0.98) (n = 19, 1 study).We considered that the study also provided the best available data to address our second objective (B). At baseline, 15 participants were clinically suspected of having DLB. In this group, (123)I-FP-CIT SPECT scanning analysed semiquantitatively had a sensitivity of 1.00 (95% CI 0.63 to 1.00) and a specificity of 1.00 (95% CI 0.59 to 1.00) for the diagnosis of DLB (n = 15, 1 study). Analysed visually, accuracy in this group was lower with a sensitivity of 0.83 (95% CI 0.36 to 1.00) and a specificity of 0.71 (95% CI 0.29 to 0.96) (n = 13, 1 study).
  
  
  CONCLUSIONS
  Only one study has used a neuropathological reference standard to assess the accuracy of DAT imaging for the diagnosis of DLB. The small size of the included study means that sensitivity and specificity estimates are imprecise. However, data from this study suggest that DAT imaging is more accurate than clinical diagnosis. Clinical diagnosis is therefore unsuitable to use as a reference standard for assessing the accuracy of DAT imaging.No studies using a neuropathological reference standard have directly addressed the common clinical scenario where the use of DAT imaging is considered as a diagnostic test in a person with possible DLB, or assessed the accuracy of DAT imaging in people with mild dementia. However, the data from the included study suggest that, where there is moderately severe dementia and a strong pre-existing suspicion of DLB (probable DLB), then a normal (123)I-FP-CIT SPECT scan may be an accurate means of excluding the diagnosis.Semiquantitative ratings of (123)I-FP-CIT SPECT scans appeared to be more accurate than visual ratings in all analyses.
authors: Oxford Health NHS Foundation Trust, Elms Centre, Oxford Road, Banbury, Oxfordshire, UK, OX16 9AL.
authors: Jenny
authors: J
authors: McCleery
authors: Shirlony
authors: S
authors: Morgan
authors: Kevin M
authors: KM
authors: Bradley
authors: Anna H
authors: AH
authors: Noel-Storr
authors: Olaf
authors: O
authors: Ansorge
authors: Chris
authors: C
authors: Hyde
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology; D003937:Diagnosis, Differential; D050483:Dopamine Plasma Membrane Transport Proteins; D006801:Humans; D007457:Iodine Radioisotopes; D020961:Lewy Body Disease / Q000000981:diagnostic imaging* / Q000473:pathology; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D007457:Iodine Radioisotopes; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane
references: J Nucl Med. 2012 Jan;53(1):154-63
references: 22159160
references: J Nucl Med. 2009 Oct;50(10):1638-45
references: 19759102
references: J Geriatr Psychiatry Neurol. 2002 Winter;15(4):182-7
references: 12489913
references: Neurology. 2005 Dec 27;65(12):1863-72
references: 16237129
references: Neurology. 1996 Nov;47(5):1113-24
references: 8909416
references: J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1063-70
references: 22869921
references: Ann Neurol. 2004 Jun;55(6):774-80
references: 15174011
references: Lancet Neurol. 2007 Apr;6(4):305-13
references: 17362834
references: Arch Neurol. 2004 Jun;61(6):919-25
references: 15210531
references: Neurology. 1999 Dec 10;53(9):1974-82
references: 10599768
references: Dement Geriatr Cogn Disord. 2008;25(3):195-205
references: 18204253
references: Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):213-27
references: 23160999
references: Neurol Sci. 2003 Oct;24(3):162-3
references: 14598067
references: Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):188-97
references: 22089660
references: JAMA. 2005 Oct 19;294(15):1934-43
references: 16234500
references: J Clin Psychiatry. 2005 May;66(5):633-7
references: 15889951
references: J Neurol. 2010 Mar;257(3):359-66
references: 19795154
references: Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S51-7
references: 18214473
references: Lancet Neurol. 2004 Jan;3(1):19-28
references: 14693108
references: Brain. 2012 Sep;135(Pt 9):2798-808
references: 22961551
references: Ann Intern Med. 2011 Oct 18;155(8):529-36
references: 22007046
references: Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
references: 12498954
references: J Neurol Sci. 1990 Feb;95(2):119-39
references: 2157823
references: J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):134-40
references: 12122169
references: Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50
references: 19838702
references: Clin Chem. 2005 Aug;51(8):1335-41
references: 15961549
references: Mov Disord. 2009;24 Suppl 2:S754-9
references: 19877236
references: Age Ageing. 2005 Nov;34(6):561-6
references: 16267179
references: J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1176-81
references: 17353255